Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation

Journal of Cellular Biochemistry

Volumn 108, Issue 4, 2009, Pages 867-876

  Ranzato, Elia ^a   Grosso, Stefano ^a,b   Patrone, Mauro ^a   Betta, Pier Giacomo ^c   Viarengo, Aldo ^a   Biffo, Stefano ^a,b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b DIBIT   (Italy)

^c C Arrigo Children's Hospital   (Italy)

Author keywords

Fibronectin; Initiation; Mesothelioma; mTOR

Indexed keywords

CYCLOHEXIMIDE; FIBRONECTIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; DRUG ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; CYCLOHEXIMIDE; FIBRONECTINS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM METASTASIS; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; SIROLIMUS; TRANSCRIPTION FACTORS;

MAMMALIA;

EID: 70350458679     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22316     Document Type: Article

References (34)

1. Adiseshaiah P, Lindner D, Kalvakolanu D, Reddy S. 2007. FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res 67:6204-6211. (Pubitemid 47037501)
2. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC. 2008. mTOR contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 283(9):13021-13030.
3. Benecke BJ, Ben-Ze'ev A, Penman S. 1978. The control of mRNA production, translation and turnover in suspended and reattached anchorage-dependent fibroblasts. Cell 14:931-939.
4. Ceci M, Gaviraghi C, Gorrini C, Sala LA, Offenhauser N, Marchisio PC, Biffo S. 2003. Release of eIF6 (p27BBP) from the 60S subunit allows 80S ribosome assembly. Nature 426:579-584. (Pubitemid 37522646)
5. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. 2000. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 20:1436-1447. (Pubitemid 30069263)
6. Emri S, Ustundag Y, Budak T, Karakoca Y, Ozdemir O. 1997. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma. Monaldi Arch Chest Dis 52:335-338. (Pubitemid 27503953)
7. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. 2008. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 5:136-147. (Pubitemid 351972085)
8. Gorrini C, Loreni F, Gandin V, Sala LA, Sonenberg N, Marchisio PC, Biffo S. 2005. Fibronectin controls cap-dependent translation through beta1 integrin and eukaryotic initiation factors 4 and 2 coordinated pathways. Proc Natl Acad Sci USA 102:9200-9205. (Pubitemid 40923541)
9. Goudar RK. 2007. Management options for malignant pleural mesothelioma: Clinical and cost considerations. Drugs 67:1149-1165. (Pubitemid 46871025)
10. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6:1122-1128. (Pubitemid 39468014)
11. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, Tempst P, Sabatini DM. 2003. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 11:895-904. (Pubitemid 36566312)
12. Klominek J, Robert KH, Sundqvist KG. 1993. Chemotaxis and haptotaxis of human malignant mesothelioma cells: Effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 53:4376-4382. (Pubitemid 24146793)
13. Klominek J, Sumitran KS, Hauzenberger D. 1997. Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: The role of beta1 integrins. Int J Cancer 72:1034-1044. (Pubitemid 27433570)
14. Kumano M, Miyake H, Kurahashi T, Yamanaka K, Fujisawa M. 2008. Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle. Br J Cancer 98:356-362. (Pubitemid 351161256)
15. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y. 2005. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 46:454-460. (Pubitemid 40270322)
16. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. 2006. mTOR, translation initiation and cancer. Oncogene 25:6416-6422.
17. Nalini M, Kim Y. 2007. A putative protein translation inhibitory factor encoded by Cotesia plutellae bracovirus suppresses host hemocyte-spreading behavior. J Insect Physiol 53:1283-1292. (Pubitemid 47633593)
18. Neuhoff V, Arold N, Taube D, Ehrhardt W. 1988. Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 9:255-262. (Pubitemid 18152745)
19. Neumeier R, Reutter W. 1985. Hepatocyte adhesion on plastic. Different mechanisms for serum- and fibronectin-mediated adhesion. Exp Cell Res 160:287-296.
20. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG. 2004. Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 45(1):37-43. (Pubitemid 38917112)
21. Orengo AM, Spoletini L, Procopio A, Favoni RE, De CA, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, Mutti L. 1999. Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 13:527-534. (Pubitemid 29180160)
22. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. 1996. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98:2277-2283. (Pubitemid 26394201)
23. Reiter T, Penman S, Capco DG. 1985. Shape-dependent regulation of cytoskeletal protein synthesis in anchorage-dependent and anchorage-independent cells. J Cell Sci 76:17-33. (Pubitemid 16246167)
24. Ruoslahti E, Hayman EG, Pierschbacher M, Engvall E. 1982. Fibronectin: Purification, immunochemical properties, and biological activities. Methods Enzymol 82:803-831.
25. Sakakibara K, Liu B, Hollenbeck S, Kent KC. 2005. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 288:2861-2868. (Pubitemid 40720668)
26. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302. (Pubitemid 38991819)
27. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
28. Schlaepfer DD, Hanks SK, Hunter T, van der GP. 1994. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature 372:786-791.
29. Smythe WR, Hwang HC, Amin KM, Eck SL, Davidson BL, Wilson JM, Kaiser LR, Albelda SM. 1994. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system. Cancer Res 54:2055-2059.
30. Stenn KS, Madri JA, Tinghitella T, Terranova VP. 1983. Multiple mechanisms of dissociated epidermal cell spreading. J Cell Biol 96:63-67. (Pubitemid 13155561)
31. Waring P. 1990. DNA fragmentation induced in macrophages by gliotoxin does not require protein synthesis and is preceded by raised inositol triphosphate levels. J Biol Chem 265:14476-14480. (Pubitemid 20281831)
32. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW. 2006. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66:7639-7646. (Pubitemid 44289221)
33. Wittelsberger SC, Kleene K, Penman S. 1981. Progressive loss of shape-responsive metabolic controls in cells with increasingly transformed phenotype. Cell 24:859-866. (Pubitemid 11071324)
34. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, Tamm M, Black JL, Roth M. 2006. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: A comparison between mesothelioma and mesothelial cells. J Cell Physiol 207:540-552.